(Q37112739)

18 August 2017

Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines (English)

1 reference

18 August 2017

0 references

1 reference

14

Rino Rappuoli

1 reference

18 August 2017

9

Simone Bufali

1 reference

18 August 2017

Cecilia Buonsanti

1

1 reference

18 August 2017

Cristiana Balocchi

2

1 reference

18 August 2017

Carole Harfouche

3

1 reference

18 August 2017

Federica Corrente

4

1 reference

18 August 2017

Luisa Galli Stampino

5

1 reference

18 August 2017

Francesca Mancini

6

1 reference

18 August 2017

Marta Tontini

7

1 reference

18 August 2017

Padma Malyala

8

1 reference

18 August 2017

Barbara Baudner

10

1 reference

18 August 2017

Ennio De Gregorio

11

1 reference

18 August 2017

Nicholas M Valiante

12

1 reference

18 August 2017

Derek T O'Hagan

13

1 reference

18 August 2017

Ugo D'Oro

15

1 reference

18 August 2017

language of work or name

English

0 references

publication date

21 July 2016

1 reference

18 August 2017

1 reference

18 August 2017

6

1 reference

18 August 2017

29063

1 reference

Creative Commons Attribution 4.0 International

18 August 2017

start time

1 July 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/srep29063

0 references

cites work

One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Interleukin-17 and innate immunity in infections and chronic inflammation

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

The design of semi-synthetic and synthetic glycoconjugate vaccines

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Immunological mechanisms of vaccination

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Use of defined TLR ligands as adjuvants within human vaccines.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Glycoconjugate vaccines and immune interference: A review

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

How bacterial carbohydrates influence the adaptive immune system

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Innate immunity of the newborn: basic mechanisms and clinical correlates

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Recent advances in the discovery and delivery of vaccine adjuvants

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Lymphokine control of in vivo immunoglobulin isotype selection.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Rational design of small molecules as vaccine adjuvants.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

From empiricism to rational design: a personal perspective of the evolution of vaccine development.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

Alum's adjuvant action: grease is the word.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4954951

A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSREP29063

Oil-in-water emulsion adjuvant with influenza vaccine in young children

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27439378

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SREP29063

1 reference

18 August 2017

1 reference

18 August 2017

1 reference